Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy1

Transplantation

Volumn 63, Issue 4, 1997, Pages 570-577

  Wee, Siewlin ^a   Pascual, Manuel ^a   Eason, James D ^a,d   Schoenfeld, David A ^b   Phelan, Joanne ^a   Boskovic, Svetlan ^a   Blosch, Consuelo ^c   Mohler, Kendall ^c   Cosimi, A Benedict ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c AMGEN INC   (United States)

^d WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 3; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY GRAFT REJECTION; NONHUMAN; PRIORITY JOURNAL;

DIMERIZATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MUROMONAB-CD3; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031051584     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199702270-00015     Document Type: Article

References (38)

1. Old LJ. Tumor necrosis factor. Sci Am 1988; 258: 41.
2. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411.
3. Loetscher H, Gentz R, Zulauf M, et al. Recombinant 55-kDa tumor necrosis factor (TNF) receptor: stoichiometry of binding to TNFα and TNFβ and inhibition of TNF activity. J Biol Chem 1991; 266: 18324.
4. Schoenfeld HJ, Poeschl B, Frey JR, et al. Efficient purification of recombinant human tumor necrosis factor beta from Escherichia coli yields biologically active protein with a trimeric structure that binds to both tumor necrosis factor receptors. J Biol Chem 1991; 266: 3863.
5. Shalaby MR, Sunden A, Loetscher H, et al. Binding and the regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med 1990; 171: 415.
6. Naume R, Shalaby R, Lesslauer W, Espevik T. Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J Immunol 1991; 146: 3045.
7. Tartaglia LA, Goeddel DV. Two TNF-receptors. Immunol Today 1992; 13: 151.
8. Seckinger P, Isaa S, Dayer JM. Purification and biological characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 1989; 264: 11966.
9. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264: 11974.
10. Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med 1989; 170: 1409.
11. Fernandez-Botran R, Vitetta, ES. Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J Exp Med 1991; 174: 673.
12. Fanslow WC, Clifford K, VandenBos T, et al. A soluble form of the interleukin 4 receptor in biological fluids. Cytokine 1990; 2: 398.
13. Michie HR, Manogue K, Spriggs, DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481.
14. Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485.
15. Girardin E, Roux-Lombard P, Grau GE, et al. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992; 76: 20.
16. Herbelin, A, Chatenoud L, Roux-Lombard P, et al. In vivo soluble tumor necrosis factor receptor release in OKT3-treated patients: differential regulation of TNF-sR55 and TNF-sR75. Transplantation 1995; 59: 1470.
17. Finkelman FD, Madden KB, Morris SC, et al. Anti-cytokine antibodies as carrier proteins: prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 151: 1235.
18. Lu ZY, Brochier J, Wijdenes J, et al. High amounts of circulating IL6 in the form of monomeric immune complexes during anti-IL6 therapy: towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 1992; 22: 2819.
19. May LT, Neta R, Moldawer LL, et al. Antibodies chaperone circulating IL-6: paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J Immunol 1993; 151: 3225.
20. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20: 259.
21. Huang D, Reittie JE, Stephens S, Hoffbrand AV, Brenner MV. Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukemia. Curr Top Microbiol Immunol 1992; 182: 237.
22. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323.
23. Sato TA, Widmer MB, Finkelman ED, et al. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 1993; 150: 2717.
24. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548.
25. Charpentier B, Hiesse C, Lantz O, et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 1992; 54: 997.
26. Debets JMH, Leunissen KML, Van Hooff HJ, Can der Linden CJ, Buurman WA. Evidence of involvement of tumor necrosis factor in adverse reactions during treatment of kidney allograft rejection with antithymocyte globulin. Transplantation 1989; 47: 487.
27. Eason JD, Pascual M, Wee SL, et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor (rhuT-NFR:Fc) for prevention of OKT3-associated acute clinical syndrome (OKT3-ACS). Transplantation 1996; 61: 224.
28. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 1984; 68: 167.
29. Miller R. Simultaneous statistical inference. New York: Springer-Verlag, 1981: 15.
30. Nam MH, Reda D, Boujoukos AJ, Agosti J, Suffredini AF. Recombinant human dimeric tumor necrosis factor (TNF) receptor (TNFR:Fc): safety and pharmacokinetics in human volunteers. Clin Res 1993; 41: 249A.
31. Yokota S, Geppert TD, Lipsky PE. Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor. J Immunol 1988; 140: 531.
32. Ware CF, Crowe PD, Vanarsdale TL, et al. Tumor necrosis factor (TNF) receptor expression in T lymphocytes: differential regulation of the type I TNF receptor during activation of resting and effector T cells. J Immunol 1991; 147: 4229.
33. Eason JD, Wee SL, Kawai T, et al. Inhibition of the effects of the TNF in renal allograft recipients using recombinant human tumor necrosis factor receptors. Transplantation 1995; 59: 300.
34. Alegre ML, Vandenabeele P, Depierreux M, et al. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. J Immunol 1991; 146: 1184.
35. Chatenoud L, Legendre C, Ferran C, et al. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-dosage and kinetics prerequisites. Transplantation 1991; 51: 334.
36. Pascual M, Duchosal MA, Steiger G, et al. Circulating soluble CR1 (CD35): serum levels in diseases and evidence for its release by human leukocytes. J Immunol 1993; 151: 1702.
37. Raasveld MHM, Bemelman FJ, Schellenkens PA, et al. Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int 1993; 43: 1140.
38. Ferran C, Dy M, Schreiber R, et al. Cytokine related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990; 20: 509.